A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
Khan KD, Emmanouilides C, Benson DM Jr, Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, Porcu P, Eisenbeis CF, Banks AL, Chen L, Byrd JC, Caligiuri MA.
Khan KD, et al. Among authors: hurst d.
Clin Cancer Res. 2006 Dec 1;12(23):7046-53. doi: 10.1158/1078-0432.CCR-06-1571.
Clin Cancer Res. 2006.
PMID: 17145827
Clinical Trial.